About 15 results found for searched term "ERK5-IN-2" (0.133 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M9688 | ERK5-IN-2 | ERK |
| ERK5-IN-2 is a selective, orally active, sub-micromolar ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. | ||
| M2734 | GSK2606414 | PERK |
| GSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM, displaying at least 100-fold selectivity over the other EIF2AKs assayed. | ||
| M3668 | GDC-0994 | ERK |
| Ravoxertinib | ||
| Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with IC50 of 6.1 nM and 3.1 nM against ERK1 and ERK2, respectively. | ||
| M4819 | XMD17-109 | ERK |
| ERK5-IN-1 | ||
| XMD17-109 (ERK5-IN-1) is a novel, specific inhibitor of ERK-5 with an EC50 value of 4.2 μM in HEK293 cells. | ||
| M9510 | JWG-071 | ERK |
| JWG-071 is the first reported kinase-selective chemical probe for ERK5, inhibits ERK5 and LRRK2 with IC50 of 88 and 109 nM, respectively. | ||
| M11529 | Temuterkib | ERK |
| LY3214996 | ||
| Temuterkib (LY3214996) is a selective, novel erK1/2 inhibitor with an IC50 of 5 nM against ERK1 and ERK2. It can effectively inhibit intracellular P-RSK1 in cancer cell lines with BRAF and RAS mutations. Temuterkib has strong antitumor activity in cancer models with altered MAPK pathways. | ||
| M14152 | ERK1/2 inhibitor 1 | ERK |
| ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively. | ||
| M14155 | Ulixertinib hydrochloride | ERK |
| BVD-523 hydrochloride; VRT752271 hydrochloride | ||
| Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. | ||
| M20811 | XMD8-85 (ERK5-IN-1) | ERK |
| XMD8-85 (ERK5-IN-1) is a selective and potent inhibitor of ERK5 and LRRK2 with IC50s of 0.162 μM and 0.339 μM, respectively. | ||
| M21071 | MAP855 | MEK |
| MAP855 is a potent, selective and orally effective ATP-competitive MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 inhibits wild-type and mutant MEK1/2 equally. | ||
| M30754 | PT-262 | ROCK |
| PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity. | ||
| M42116 | ERK-IN-7 | ERK |
| ERK-IN-7, an analogue of SHR2415, is a potent ERK inhibitor with IC50 of 5 nM and 7 nM against ERK1 and ERK2, respectively. | ||
| M45287 | CK2/ERK8-IN-1 | Casein Kinase |
| CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) (Ki 0.25 µM) and ERK8 (MAPK15, ERK7), both with IC50s of 0.50 µM. In addition, CK2/ERK8-IN-1 binds to PIM1, HIPK2, and DYRK1A with Ki values of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. 15.25 µM and 11.9 µM, respectively, and also has pro-apoptotic activity. | ||
| M49702 | ERK1/2 inhibitor 4 | ERK |
| ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. | ||
| M49703 | ERK1/2 inhibitor 5 | ERK |
| ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
